Sign In
Buy GLPG
$27.38
+0.0650 (+0.238%)
At Close: Jun 03, 2026
Galapagos NV (GLPG) CEO Onno van de Stolpe on Q2 2021 Results - Earnings Call Transcript
12:20pm, Saturday, 07'th Aug 2021
Galapagos NV (GLPG) CEO Onno van de Stolpe on Q2 2021 Results - Earnings Call Transcript
Here's Why Galapagos Stock Is Falling Today
04:20pm, Thursday, 15'th Jul 2021
The company's new salt-inducable kinase inhibitor program is getting off to a rocky start.
Galapagos (GLPG) Falls on Inflammatory Study Data Readout
01:08pm, Thursday, 15'th Jul 2021
Galapagos (GLPG) announces data from multiple studies evaluating its two inflammatory candidates - GLPG3970 and GLPG3667. Stock down.
Galapagos' Another Psoriasis Candidate Shows Efficacy, Safety Profile In Mid-Stage Study
05:49am, Thursday, 15'th Jul 2021
Galapagos NV (NASDAQ: GLPG) reported topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patients. At Week 4, four out of 10 patients in the high dose
Galapagos Shares Drop As SIK Inhibitor Fails To Show Positive Outcomes In Ulcerative Colitis, Rheumatoid Arthritis Patients
05:45am, Thursday, 15'th Jul 2021
Galapagos NV (NASDAQ: GLPG) reports topline results from three studies evaluating GLPG3970, a SIK inhibitor, in psoriasis, ulcerative colitis (UC), and rheumatoid arthritis (RA). 26-patient CALOSO
Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation
04:01pm, Wednesday, 14'th Jul 2021
Mechelen, Belgium; 14 July 2021; 2 2 . 01 CET ; regulated information – Galapagos NV (Euronext & Nasda q : GLPG) reports topline results with GLPG3970 in three pati e nt studies . GLPG3970 , the fir
Galapagos: It's Not As Bad As Valued By The Market
12:48pm, Thursday, 24'th Jun 2021
Galapagos has over $6.2 billion in cash with no debt and a market capitalization of only $4.5 billion. The company has an approved product that is expected to generate €500 million annually in sales
Galapagos announces departure of CSO Piet Wigerinck later this year
04:01pm, Tuesday, 22'nd Jun 2021
Mechelen, Belgium; 22 June 202 1 , 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces the departure of Dr. Piet Wigerinck later this year .
Galapagos NV (GLPG) CEO Onno van de Stolpe on Q1 2021 Results - Earnings Call Transcript
08:24pm, Friday, 07'th May 2021
Galapagos NV (GLPG) CEO Onno van de Stolpe on Q1 2021 Results - Earnings Call Transcript
Galapagos Drops Early Metabolic & Osteoarthritis Programs, Reorganizes R&D Efforts
03:49pm, Friday, 07'th May 2021
Galapagos NV (NASDAQ: GLPG) is chopping its pipeline to conserve cash while its business development team pursues a mission to find a “transformative” deal for the company. The company is ditc
Galapagos creates new subscription right plans
04:01pm, Friday, 30'th Apr 2021
Mechelen, Belgium ; 30 April 2021 , 22.01 CET; regulated information – – Galapagos NV (Euronext & NASDAQ : GLPG) announced today that its supervisory b oard created 2, 7 36,250 subscription rig
e-therapeutics reaches two key milestones in Galapagos collaboration
03:26am, Friday, 23'rd Apr 2021
e-therapeutics PLC (LON:ETX) has reached two key milestones in its collaboration with Galapagos NV, triggering two payments to the company. The two operational and success-based milestones were defin
e-therapeutics sees two key milestones in Galapagos collaboration
02:41am, Friday, 23'rd Apr 2021
e-therapeutics plc (LON:ETX) has reached two key milestones in its collaboration with Galapagos NV, triggering two payments to the company. The two operational and success-based milestones were define
Galapagos May Finally Get Around Its CRL Situation
06:36am, Tuesday, 23'rd Mar 2021
Galapagos received a CRL on filgotinib in rheumatoid arthritis.
Galapagos increases share capital through subscription right exercises
05:01pm, Friday, 19'th Mar 2021
Mechelen, Belgium; 19 March 2021, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.
